These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 39012398)
1. Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China. Chen Y; Cao Q; Peng C; Zhou B; Jiang Y; Chen X; Li J Front Med; 2024 Aug; 18(4):752-756. PubMed ID: 39012398 [No Abstract] [Full Text] [Related]
3. Journal club: New small molecules for atopic dermatitis management. Lefevre MA; Mohme S; Alband N; Nogueira M; Rosell Diaz A; Rodriguez-Lomba E Eur J Dermatol; 2021 Dec; 31(6):849-852. PubMed ID: 35107077 [No Abstract] [Full Text] [Related]
4. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals. Melikhov O; Kruglova T; Lytkina K; Melkonyan G; Prokhorovich E; Putsman G; Rodoman G; Vertkin A; Zagrebneva A; Stebbing J Ann Rheum Dis; 2021 Sep; 80(9):1245-1246. PubMed ID: 34099486 [No Abstract] [Full Text] [Related]
5. Review of the use of Janus kinase inhibitors in the treatment of scarring alopecia. Nohria A; Desai D; Shapiro J; Bordone L; Lo Sicco K Int J Dermatol; 2024 Jun; 63(6):e105-e110. PubMed ID: 38571280 [No Abstract] [Full Text] [Related]
6. Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis. Navarrete-Rodríguez EM; Larenas-Linnemann D; Vidaurri de la Cruz H; Luna-Pech JA; Guevara Sanginés E Curr Allergy Asthma Rep; 2024 Sep; 24(9):485-496. PubMed ID: 39105881 [TBL] [Abstract][Full Text] [Related]
7. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039 [TBL] [Abstract][Full Text] [Related]
8. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching. Dhir B; Meena SK; Sardana K; Sharath S Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552 [TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of new JAK inhibitors under development. Just more of the same? Westhovens R Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i27-i33. PubMed ID: 30806706 [TBL] [Abstract][Full Text] [Related]
11. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Peterson D; Damsky W; King B J Am Acad Dermatol; 2020 Jun; 82(6):e223-e226. PubMed ID: 32278797 [No Abstract] [Full Text] [Related]
12. Biological Therapies for Atopic Dermatitis: A Systematic Review. Zhou S; Qi F; Gong Y; Zhang J; Zhu B Dermatology; 2021; 237(4):542-552. PubMed ID: 33735876 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Taylor PC Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707 [TBL] [Abstract][Full Text] [Related]
14. Acute spondyloarthritis developing during successful treatment with dupilumab for severe atopic dermatitis. Raimondo A; Guglielmi G; Marino C; Ligrone L; Lembo S Clin Exp Dermatol; 2022 Mar; 47(3):592-593. PubMed ID: 34655234 [No Abstract] [Full Text] [Related]
15. Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis. Napolitano M; Foggia L; Patruno C; Gallo L; Tommasino N; Cecere D; Megna M Clin Exp Dermatol; 2024 Sep; 49(10):1232-1234. PubMed ID: 38699956 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature. Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219 [TBL] [Abstract][Full Text] [Related]
17. Comprehensive real-world comparisons between baricitinib and dupilumab treatments for moderate to severe atopic dermatitis. Cho YT; Lee MS; Chang WY; Lu YT; Chu CY; Chan TC J Allergy Clin Immunol Pract; 2024 Jul; 12(7):1924-1927.e1. PubMed ID: 38604532 [No Abstract] [Full Text] [Related]
18. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis. Wan H; Jia H; Xia T; Zhang D Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351 [TBL] [Abstract][Full Text] [Related]
19. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126 [TBL] [Abstract][Full Text] [Related]
20. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]